Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess the single dose safety, tolerability and pharmacokinetic properties of ABBV-1088 in healthy adult participants
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1- ABBV-1088 Dose A | Experimental | Participants will receive single dose of ABBV-1088 dose A on day 1 |
|
| Group 1- Placebo | Experimental | Participants will receive single dose of placebo day 1 |
|
| Group 2- ABBV-1088 Dose B | Experimental | Participants will receive single dose of ABBV-1088 dose B on day 1 |
|
| Group 2- Placebo | Experimental | Participants will receive single dose of placebo day 1 |
|
| Group 3- ABBV-1088 Dose C | Experimental | Participants will receive single dose of ABBV-1088 dose C on day 1 |
|
| Group 3- Placebo | Experimental | Participants will receive single dose of placebo day 1 |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Drug: ABBV-1088 | Drug | • Oral Capsule |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of ABBV-1088 | Cmax of ABBV-1088 | Up to approximately 11 days |
| Time to Cmax (Tmax) of ABBV-1088 | Tmax of ABBV-1088 | Up to approximately 11 days |
| Terminal Phase Elimination Rate Constant (Beta) of ABBV-1088 | Terminal phase elimination rate constant (beta) of ABBV-1088 | Up to approximately 11 days |
| Terminal Phase Elimination Half-Life (t1/2) of ABBV-1088 | Terminal phase elimination half-life of ABBV-1088 | Up to approximately 11 days |
| Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-1088 | AUCt of ABBV-1088 | Up to approximately 11 days |
| Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-1088 | AUCinf of ABBV-1088 | Up to approximately 11 days |
| Number of Participants With Adverse Events (AEs) | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study | Up to Day 32 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Acpru /Id# 264249 | Grayslake | Illinois | 60030 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Group 4- ABBV-1088 Dose D | Experimental | Participants will receive single dose of ABBV-1088 dose D on day 1 |
|
| Group 4- Placebo | Experimental | Participants will receive single dose of placebo day 1 |
|
| Group 5- ABBV-1088 Dose E | Experimental | Participants will receive single dose of ABBV-1088 dose E on day 1 |
|
| Group 5- Placebo | Experimental | Participants will receive single dose of placebo day 1 |
|
| Group 6- ABBV-1088 Dose F | Experimental | Participants will receive single dose of ABBV-1088 dose F on day 1 |
|
| Group 6- Placebo | Experimental | Participants will receive single dose of placebo day 1 |
|
| Drug: Placebo for ABBV-1088 | Drug | • Oral Capsule |
|